A group of 47 Democratic lawmakers from the House and Senate is urging FDA to finalize a proposed rule that effectively would require generic drug makers update safety information on their labels before the agency makes a final determination instead of adopting an industry alternative. The lawmakers wrote to FDA Friday (April 24) that the alternative negotiated by the generic and brand pharmaceutical drug lobby groups, which would require FDA make a final determination before any safety information is updated,...